SCHEMBL2909765

SCHEMBL2909765

CCCc1nc(NCCCC2CCN(C)CC2)ncc1-c1nc2c(C)c(C)ccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 14/20 1.00
FLT3 P36888 4/20 0.38
TYRO3 Q06418 4/20 0.38
GAS6 Q14393 4/20 0.38
MERTK Q12866 3/20 0.35
AXL P30530 1/20 0.35
NMT1 P30419 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912396 0.92 HRH4 (0.85) HRH4FLT3TYRO3GAS6MERTK
SCHEMBL2912935 0.89 HRH4 (0.84) HRH4FLT3TYRO3GAS6
SCHEMBL2909136 0.87 HRH4 (0.77) HRH4FLT3TYRO3GAS6MERTK
SCHEMBL2909393 0.87 HRH4 (0.85) HRH4FLT3TYRO3GAS6
SCHEMBL2910094 0.86 HRH4 (0.75) HRH4FLT3TYRO3GAS6
SCHEMBL2906280 0.85 HRH4 (0.74) HRH4FLT3TYRO3GAS6MERTK
SCHEMBL2909049 0.85 HRH4 (0.83) HRH4
SCHEMBL2913838 0.83 HRH4 (0.82) HRH4FLT3TYRO3GAS6MERTK
SCHEMBL2906292 0.81 HRH4 (0.81) HRH4FLT3TYRO3GAS6
SCHEMBL603807 0.81 HRH4 (1.00) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598189-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2013-12-03 US claimed
US-20130072510-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (US) 2013-03-21 US claimed
US-8343989-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2013-01-01 US claimed
US-20100256373-A1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR EDWARDS JAMES P 2010-10-07 US claimed
EP-2007752-B1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2010-08-18 EP claimed
US-20090137608-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor EDWARDS JAMES P 2009-05-28 US claimed
EP-2007752-A4 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2009-04-22 EP claimed
US-7507737-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2009-03-24 US claimed
EP-2007752-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-31 EP claimed
WO-2007117399-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO claimed
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-18 US claimed
US-9365548-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-06-14 US disclosed
US-9365548-B2 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2016-06-14 US disclosed
US-20150148361-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2015-05-28 US disclosed
US-20150148361-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2015-05-28 US disclosed
WO-2007117399-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO disclosed
WO-2007117399-A2 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-18 WO disclosed
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-18 US disclosed
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-18 US disclosed
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244126-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 HRH4 1/4885FLT3 929/4885TYRO3 315/4885
US-20090137608-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 HRH4 1/4885FLT3 894/4885TYRO3 296/4885
US-20100256373-A1 BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR HRH4, HRH2, HRH3 HRH4 1/4885FLT3 894/4885TYRO3 296/4885
US-20150148361-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 HRH4 1/4885FLT3 929/4885TYRO3 315/4885
US-20130072510-A1 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor HRH4, HRH2, HRH3 HRH4 1/4885FLT3 894/4885TYRO3 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.